6 completed, 1 recruiting, 1 terminated, 1 withdrawn. 9 Phase 2, 3 Phase 3.
By phase and status
Follow nirmatrelvir: new trials by email Literature Review of nirmatrelvir trials Research Report on nirmatrelvir
Trials (filtered) newest first · largest first
All 9 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
Nirmatrelvir, Ritonavir, Placebo - Long COVID | Phase 2 | Completed | 100 | 2023-04-14 | 2024-12-02 |
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19) | Phase 2 | Withdrawn | | 2022-12-13 | 2023-03-01 |
Paxlovid for Treatment of Long Covid
Nirmatrelvir, Placebo, Ritonavir - Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID | Phase 2 | Completed | 168 | 2022-11-08 | 2025-09-04 |
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
nirmatrelvir, ritonavir, placebo for nirmatrelvir - COVID-19 | Phase 2 | Completed | 436 | 2022-10-19 | 2024-10-08 |
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - COVID-19 | Phase 2 | Completed | 158 | 2022-08-03 | 2024-09-23 |
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | 3800 | 2021-09-30 | 2026-02-19 |
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
PF-07321332, Placebo for PF-07321332, Placebo for Ritonavir - COVID-19 | Phase 2 / Phase 3 | Completed | 2954 | 2021-09-09 | 2023-05-06 |
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
PF-07321332, Ritonavir, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | 1440 | 2021-08-25 | 2023-08-14 |
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
PF-07321332, Ritonavir, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | 2091 | 2021-07-16 | 2025-07-10 |
Conditions studied
COVID-19 (7) · Post-Acute COVID-19 Syndrome (2) · COVID-19 rebound (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Sponsors
Pfizer (6) · Harlan M Krumholz (1) · Stanford University (1) · University of Oxford (1)
Countries
United States (8) · Brazil (5) · Bulgaria (5) · Hungary (4) · Mexico (4) · Spain (4) · Thailand (4) · Argentina (3) · Colombia (3) · Czechia (3) · Japan (3) · Malaysia (3) · Poland (3) · South Africa (3) · Turkey (Türkiye) (3)
Top investigators
Akiko Iwasaki, PhD (1) · Harlan M Krumholz, MD, SM (1) · Linda Geng, MD, PhD (1) · Upinder Singh, MD (1)
Results publications
PMID 40592258, PMID 35172054, PMID 36803992, PMID 37470445, PMID 37778363, PMID 38225598, PMID 38598573, PMID 38677300, PMID 38848477, PMID 39018532, PMID 39523543, PMID 39896880, PMID 40188838, PMID 40675169, PMID 40788441, PMID 40809391, PMID 40810942, PMID 41027009, PMID 41082886, PMID 41085942, PMID 41321979, PMID 41857593